Balyasny Asset Management
IMDX

Balyasny Asset Management’s Insight Molecular Diagnostics IMDX Stock Holding History

Balyasny Asset Management’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,644
Closed -$39K – 3091
2022
Q3 		$39K Buy
2,644
+2,104
+390% +$36.4K ﹤0.01% 2499
2022
Q2 		$10K Buy
+540
New +$12.3K ﹤0.01% 2582

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Balyasny Asset Management's IMDX Position: Q4 2022 in Review

Balyasny Asset Management sold out of Insight Molecular Diagnostics (IMDX) in Q4 2022, closing a stake of 2,644 shares — an estimated $39K sold.

Balyasny Asset Management first reported a position in IMDX in Q2 2022 and held it in 2 quarters. The position peaked at $39K in Q3 2022. 58 funds tracked by Wall St. Rank hold IMDX as of Q4 2022.

  • Balyasny Asset Management reported no remaining Insight Molecular Diagnostics position as of Q4 2022 after selling out during the quarter.
  • Balyasny Asset Management sold 2,644 Insight Molecular Diagnostics shares in Q4 2022, an estimated $39K.
  • Balyasny Asset Management first reported a position in Insight Molecular Diagnostics in Q2 2022 and held it in 2 quarters.
  • Balyasny Asset Management's Insight Molecular Diagnostics position peaked at $39K in Q3 2022.
  • 58 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q4 2022.

Based on Balyasny Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.